A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Galinpepimut S (Primary) ; Montanide ISA-51; Sargramostim
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 08 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 08 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.